Compare Quest Diagnostics Inc (DGX) vs Xcel Energy Inc (XEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Xcel Energy Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Xcel Energy Inc trades at $73.77 (market cap $45.82B). The key difference: Xcel Energy Inc is the larger of the two by market cap, and Xcel Energy Inc pays the higher dividend (3.23%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Xcel Energy Inc for 61 Days on average.
| DGX | XEL | |
|---|---|---|
Market Cap | $25.48B | $45.82B |
Volume | 941,866 | 6,910,516 |
Sector | Health | Utilities |
52-Week High | $247.45 | $83.91 |
52-Week Low | $173.49 | $69.39 |
Typical Hold Time | 56 Days | 61 Days |
Enterprise Value | $31.23B | $84.14B |
Dividend Yield | 1.49% | 3.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
Xcel Energy (XEL) trades at $73.46, up 1.44% today, with a bullish technical signal and consensus analyst target of $90.83 suggesting 24% upside. Recent earnings show mixed beats, with Q2 2026 EPS of $0.93 exceeding expectations. The company maintains solid profitability with a 15.28% net margin and benefits from rising data center power demand, though it faces capital expenditure pressures with a $60 billion investment plan.
The outlook is positive, driven by infrastructure investments and load growth, but risks include high debt levels, wildfire liabilities, and interest rate sensitivity. Wall Street sentiment is bullish with 63% buy ratings, but valuation concerns persist with a P/E of 20.1 above some peers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
